These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23933756)

  • 1. Novel metabolic drugs and blood pressure: implications for the treatment of obese hypertensive patients?
    Engeli S; Jordan J
    Curr Hypertens Rep; 2013 Oct; 15(5):470-4. PubMed ID: 23933756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors.
    Engeli S; Jordan J
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):468-72. PubMed ID: 24914567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Modest Weight Loss in Normalizing Blood Pressure in Obese Subjects on Antihypertensive Drugs.
    Gilardini L; Redaelli G; Croci M; Conti A; Pasqualinotto L; Invitti C
    Obes Facts; 2016; 9(4):251-8. PubMed ID: 27454447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. THE CLINICAL EXPERIENCE OF THE EFFECTIVE USE OF DAPAGLIFLOZIN IN COMORBID CARDIAC PATIENTS WITH CONCOMITANT TYPE 2 DIABETES MELLITUS AND ARTERIAL HYPERTENSION ON THE BACKGROUND OF OVERWEIGHT IN OUTPATIENT SETTING.
    Rishko OA; Derbak MA; Ihnatko YY; Dankanych YЕ; Bletskan MM; Krasnova AA; Mashura HY
    Wiad Lek; 2022; 75(10):2397-2401. PubMed ID: 36472267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
    Chrysant SG
    Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes.
    Sjöström CD; Johansson P; Ptaszynska A; List J; Johnsson E
    Diab Vasc Dis Res; 2015 Sep; 12(5):352-8. PubMed ID: 26008804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.
    Thomopoulos C; Parati G; Zanchetti A
    J Hypertens; 2017 May; 35(5):922-944. PubMed ID: 28141660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypertension and diabetes: target blood pressure and blood pressure lowering by new antidiabetic drugs].
    Kintscher U; Jacob S
    Dtsch Med Wochenschr; 2014 Nov; 139(48):2468-9. PubMed ID: 25409409
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Trends in subclinical atherosclerosis in patients with arterial hypertension associated with diabetes mellitus: a relationship between blood pressure achieved with antihypertensive therapy and body weight].
    Karpov RS; Koshel'skaia OA; Khoroshilova IV
    Ter Arkh; 2010; 82(9):23-30. PubMed ID: 21086616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.
    Abellán J; Leal M; Hernández-Menárguez F; García-Galbis JA; Martínez-Pastor A; de Vinuesa SG; Luño J
    Kidney Int Suppl; 2005 Jan; (93):S20-4. PubMed ID: 15613062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists.
    Berra C; Manfrini R; Regazzoli D; Radaelli MG; Disoteo O; Sommese C; Fiorina P; Ambrosio G; Folli F
    Pharmacol Res; 2020 Oct; 160():105052. PubMed ID: 32650058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure control in type 2 diabetes.
    de Galan BE
    N Engl J Med; 2010 Aug; 363(7):695-6; author reply 697. PubMed ID: 20842774
    [No Abstract]   [Full Text] [Related]  

  • 18. [Arterial hypertension management in patients with type 2 diabetes].
    Charpentier G; Genès N; Vaur L; Clerson P; Amar J; Guéret P; Cambou JP
    Arch Mal Coeur Vaiss; 2002; 95(7-8):661-5. PubMed ID: 12365076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.
    Tsapas A; Karagiannis T; Kakotrichi P; Avgerinos I; Mantsiou C; Tousinas G; Manolopoulos A; Liakos A; Malandris K; Matthews DR; Bekiari E
    Diabetes Obes Metab; 2021 Sep; 23(9):2116-2124. PubMed ID: 34047443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes.
    Scheen AJ; Van Gaal LF
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):911-22. PubMed ID: 24731666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.